Refine by MP, party, committee, province, or result type.
Health committee In terms of the volume?
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I don't think we have anybody here who can talk about the cross-border drug issue.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee We could provide you with some information, if you wish, at a later date.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Okay.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Alberta and Manitoba is where they are. So we have one in every province. I think there's one for all of the Atlantic.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Yes, there are seven of them now.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Can I just add something to answer your question? We're constantly scanning the media and other reports to see what's out there. As you can well imagine, a number of events and reports come to us. We have people on the ground. For example, we have seven regional offices in the m
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I'm going to ask Dr. Turner to respond to you, but I just wanted to say there are a number of issues related to mandatory reporting by health care professionals. In reporting adverse reactions, and particularly serious adverse reactions, it's more of an issue of quality rather th
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I will ask Dr Turner to answer your question.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee I would just add that the beauty of the new approach we're proposing is that you could attach the studies that Chris is talking about to the licence, so that you would be saying that based on the science and the sound science in the best interests of Canadians, we will issue a li
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee You're absolutely right that it is mandatory for manufacturers to report adverse events, but not so for health care professionals or, obviously, Canadians. In the reporting of adverse events, there is a lot of underreporting, for a variety of reasons, going on in terms of barri
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee We're doing a lot more of it, at a variety of levels.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee Yes, we are much more proactive in trying to seek opportunities to share work with them and to share reports of post-market surveillance. If they're picking up any signals in those countries, then we would have this rapid sharing of information.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee It was done before, but we've recognized that it needs to be done much, much more proactively than ever before.
January 31st, 2008Committee meeting
Meena Ballantyne
Health committee So you're seeking the definition of post-market surveillance?
January 31st, 2008Committee meeting
Meena Ballantyne